News

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.

August 5 (Reuters) - European shares rose on Wednesday as investors monitored corporate earnings and diplomatic efforts to end the U.S.-Iran war and reopen the blockaded Strait of Hormuz.

The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit

Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook